Lexeo Therapeutics Inc. has announced positive interim results from the ongoing HEROIC-PKP2 Phase I/II clinical trial evaluating LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). The company reported that LX2020 was generally well tolerated among ten participants, with no clinically significant complement activation observed. Data showed dose-dependent increases in PKP2 protein expression, with a mean increase of 93% in the low-dose cohort and 162% in high-dose cohorts. The majority of participants experienced stabilization or improvement in arrhythmia burden, including non-sustained ventricular tachycardia and premature ventricular contractions. Lexeo Therapeutics plans to present 12-month data for all high-dose participants in the fourth quarter of 2026 and anticipates regulatory engagement later that year. The interim results were presented during a company webcast on January 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623400-en) on January 12, 2026, and is solely responsible for the information contained therein.